Zeptide Pharma: Pioneering Next-Generation Oral GLP-1 Therapeutics
As a premier Investigational New Drug manufacturer, Zeptide Pharma is at the forefront of pharmaceutical innovation, actively developing and scaling next-generation once-a-week oral GLP-1 tablets. Through our specialized GLP-1 CDMO services, we support pharmaceutical partners in advancing complex peptide and metabolic therapies from clinical trial IND phases through to commercial-scale manufacturing.
The Paradigm Shift: Oral GLP-1 Tablets vs. Traditional Injections
While traditional once-a-week GLP-1 injections have revolutionized diabetes and weight management, the future of patient care lies in accessible, non-invasive delivery. As an innovative oral GLP-1 manufacturer, Zeptide Pharma is developing manufacturing solutions that offer significant clinical and commercial advantages over current injectable delivery systems:
- Enhanced Patient Compliance: Oral tablets completely eliminate needle anxiety, injection-site pain, and localized reactions, making it significantly easier for patients to adhere to their weekly medication regimens.
- Superior Convenience: A once-a-week tablet allows for discreet and simple administration at home or on the go, without the need for sharps disposal or complex injection instructions.
- Simplified Supply Chain Logistics: Traditional injectable peptides often require strict cold-chain shipping and refrigerated storage. Solid oral dosages significantly reduce logistical complexities and costs by offering greater temperature stability and extended shelf life.
- Scalable Manufacturing Efficiency: By transitioning from complex sterile fill-finish to advanced solid-dose formulation, we can achieve high-volume production more rapidly. This positions Zeptide Pharma as a highly efficient weight loss medication contract manufacturer capable of meeting explosive global demand.
Your Partner in IND Development and Scale-Up
Zeptide Pharma combines 25 years of pharmaceutical expertise with state-of-the-art facilities to bring next-generation metabolic treatments to life. Whether you require a generic diabetic drug manufacturer to scale an existing portfolio or an IND development partner to formulate the next breakthrough in oral peptide delivery, we provide the integrated solutions required to bring revolutionary, patient-friendly therapeutics to the global market.
To establish a Professional Partnership:
Contact MayMag Biologics (Formerly Tirzepatide Pharma / Zeptide Pharma)
Partner with a premier USA-based, FDA-registered 503B/506E CDMO and IND facility. As a leading sterile API manufacturer and large-scale industrial supplier, we provide comprehensive manufacturing solutions for a wide range of critical care and specialized therapeutics, including:
- Diabetic Care & Biosimilars: Insulin 70/30 pens, glargine, and advanced biosimilars.
- Injectables & Auto-Pens: Auto-injector medications and epinephrine delivery systems.
- Specialized Treatments: Weight-loss therapies, nasal sprays, and ophthalmic products.
- Essential Preparations: Sterile and bacteriostatic waters.
